Novadel Pharma Inc  

(Public, OTCMKTS:NVDL)   Watch this stock  
Find more results for PINK:NVDL
0.0000 (0.00%)
Feb 11 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.00 - 0.01
Open     -
Vol / Avg. 0.00/131,427.00
Mkt cap 1.38M
P/E     -
Div/yield     -
EPS 0.00
Shares 134.89M
Beta 1.10
Inst. own 26%

Key stats and ratios

Q3 (Sep '12) 2011
Net profit margin -194.62% -257.52%
Operating margin -200.45% -126.62%
EBITD margin - -126.62%
Return on average assets - -295.08%
Return on average equity - -
Employees 4 -
CDP Score - -


25 Minneakoning Road
United States - Map
+1-302-6365400 (Phone)
+1-302-6365454 (Fax)

Website links


NovaDel Pharma Inc. is a specialty pharmaceutical company developing oral spray formulations for a range of marketed pharmaceuticals. The Company’s oral spray technology is focused on addressing unmet medical needs for an array of existing and future pharmaceutical products. Its most advanced oral spray candidates target angina, insomnia, erectile dysfunction, migraine headaches, nausea and disorders of the central nervous system. The Company plans to develop these and other products independently and through collaborative arrangements with pharmaceutical and biotechnology companies. In August 2013, Suda Ltd announced that the acquisition of the NovaDel Pharma Inc. assets was completed.

Officers and directors

Steven B. Ratoff Chairman of the Board, President, Chief Executive Officer
Age: 72
Trading Activity - Yahoo Finance
Craig A Johnson Chief Financial Officer, Senior Vice President, Secretary
Age: 53